RAPTOR Consortium

What RAPTOR Consortium does

RAPTOR Consortium is a European research network focused on advancing Online Adaptive Particle Therapy (OAPT), primarily proton-based, for precision cancer treatment. It operates as a Marie Skłodowska-Curie Doctoral Network under EU framework programs, with the original RAPTOR phase funded under Horizon 2020 (Grant Agreement 955956) and the current RAPTORplus phase funded under Horizon Europe (Grant Agreement 101226720). The consortium trains 18 Early-Stage Researchers across 16 European institutions in collaboration with 30+ named partners spanning clinical PT centers, academic groups, and industrial vendors.

The consortium's technical portfolio targets the components required for real-time adaptation of particle therapy: prompt gamma imaging for in-vivo range verification, synthetic CT generation from MRI, CBCT enhancement, 4D MR imaging, log-based quality assurance, dose accumulation, proton radiography, and 4D anthropomorphic phantoms. AI/ML methods are embedded across multiple work packages, including computer vision for synthetic CT, anomaly detection for prompt gamma imaging, automated contouring, generative approaches for radiography analysis, and robust optimization for treatment planning. Senior PIs at PoliMi (Paganelli), UL (Jeraj), and Cosylab anchor the AI/ML work alongside physics and clinical leads at PSI, OncoRay/HZDR, Aarhus DCPT, LMU, and MGH.

RAPTOR's business model is non-commercial. There is no product revenue; inflows come from EU research grants (Horizon 2020 / Horizon Europe) and supplementary national cancer society grants. Outputs are scientific publications, a White Paper, trained researchers, and intellectual property licensed or transferred to industry partners (RaySearch, IBA, Varian, Elekta, Cosylab, MedPhoton, ProtonVDA). The customer/market relationship is one of research collaboration and talent pipeline, not paid product adoption.

Name

RAPTOR Consortium

Legal name

Helmholtz-Zentrum Dresden – Rossendorf e. V. – Institute of Radiooncology – OncoRay

Website

https://raptor-consortium.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

RAPTOR Consortium is an EU-funded Marie Skłodowska-Curie research network of 18 doctoral candidates across 16 European institutions developing online adaptive particle therapy technologies — including prompt gamma imaging, synthetic CT, and AI-driven QA — for precision proton cancer treatment.

Ownership category

akta.pro rank

Product category

Radiation Therapy Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Adaptive particle therapy
• Proton therapy research
• Medical physics training
• Radiation oncology research
• Treatment imaging verification

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. EU Research Funding (Horizon Europe): Primary funding from European Union Horizon Europe Framework Programme through Marie Skłodowska-Curie Doctoral Network grants. RAPTORplus funded under Grant Agreement No. 101226720. Previous RAPTOR (Horizon 2020) under Grant Agreement No. 955956.
2. Research Project Grants: Additional funding from national cancer societies (e.g., Dutch Cancer Society Grant 11518 - INCONTROL) and other research bodies supporting specific project activities.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

RAPTOR Consortium is an EU-funded Marie Skłodowska-Curie research and training network that develops and validates online adaptive particle therapy (OAPT) technologies for cancer treatment. Its core deliverable is the RAPTORplus Doctoral Network, which trains 18 doctoral candidates across 16 European institutions on research projects spanning imaging (CBCT, MRI, prompt gamma), treatment verification, dose accumulation, biomarker-driven adaptation, and clinical workflow automation. The consortium also operates the previous RAPTOR MSCA ITN as its foundational predecessor program.

Product overview

RAPTOR Consortium operates two interconnected research and training programmes: RAPTORplus (current Marie Skłodowska-Curie Doctoral Network with 18 doctoral candidates across 16 European institutions) builds upon the foundational RAPTOR ITN project. Together they advance right-time adaptive particle therapy through integrated research work packages covering: (1) efficient clinical implementation of online adaptive particle therapy including data processing optimization, workflow assessment, cost reduction, and paediatric applications; (2) technological completion through CBCT imaging enhancement and treatment verification using prompt gamma, fast neutrons, and iono-acoustic waves; (3) biomarker-based adaptation leveraging quantitative MRI, radiobiological models, and AI-driven treatment personalization. The consortium provides training through network-wide training camps, secondments, workshops, and educational resources.

Differentiator

Problem solved

Functional benefit

Products and services

• RAPTORplus Doctoral Network A Marie Skłodowska-Curie Doctoral Network training 18 doctoral candidates across 16 European institutions on research projects covering online adaptive proton therapy workflows, CBCT imaging, treatment verification, biomarker-based personalization, paediatric applications, and cost-effectiveness evaluation. Targets researchers, clinicians, and medical physicists.
• RAPTOR MSCA Innovative Training Network The foundational Marie Skłodowska-Curie Action Innovative Training Network that established foundations of online adaptive particle therapy (OAPT) by developing key tools, concepts, and expertise across imaging, planning, and verification to enable real-time adaptations within treatment fractions. Targeted 15 Early Stage Researchers.

Quantifiable outcome

• Reduction in treatment margins through in-vivo range verification and treatment verification
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature10 records

Partnerships

30 partnerships are on record, tiered core, strategic, partner and minor.

• Paul Scherrer Institut (PSI)coreStrategic or Co-development PartnerWorld leader in Pencil Beam Scanning and IMPT development. Hosts 2 ESR projects (ESR1 on dose accumulation, ESR10 on plan approval) and provides state-of-the-art proton therapy facilities for research. PSI PhD degree programs for consortium researchers.
• University Medical Center Groningen (UMCG)coreStrategic or Co-development PartnerFirst academic department in Netherlands with integrated photon-proton clinic treating 4,500+ patients annually. Hosts 2 ESR projects (ESR4 on MRI-guided APT, ESR15 on proton radiography). Leading model-based clinic development.
• CosylabcoreStrategic or Co-development PartnerGlobal technology company building control systems for proton therapy. Founding member of RAPTOR consortium. Hosts ESR9 on automated log-file based QA. Provides industry perspective and technology transfer capability.
• OncoRay (HZDR)coreStrategic or Co-development PartnerNational Center for Radiation in Oncology in Dresden. Hosts ESR13 on prompt-gamma treatment verification. Website legal entity and data controller. Pioneered first clinical PGI implementation in 2015.
• GSI HelmholtzzentrumcoreStrategic or Co-development PartnerOperates unique accelerators for heavy ions. Hosts ESR8 on real-time 4D-dose calculation for motion mitigation. Contributes expertise in particle therapy research and development.
• Ludwig-Maximilians-Universität München (LMU)coreStrategic or Co-development PartnerLeading physics faculty in Germany. Hosts ESR14 on dose quantification from PG imaging. Department of Medical Physics addresses core topics of ion beam therapy with emphasis on image guidance.
• MedPhotoncoreStrategic or Co-development PartnerSalzburg-based company developing robotic imaging solutions including CBCT systems for adaptive particle therapy. Hosts ESR3 on CBCT enhancement strategies. ImagingRing product developer.
• RaySearch LaboratoriescoreStrategic or Co-development PartnerMedical technology company developing treatment planning software. Hosts ESR11 on robust optimization considering uncertainties. Provides industry software platform for treatment planning research.
• Aarhus University (DCPT)coreStrategic or Co-development PartnerDanish Centre for Particle Therapy - only facility in Denmark. Hosts ESR7 on robust optimization for anatomical variations. Integrates proton therapy with comprehensive research center.
• Medical University of Vienna (MedUniVienna)coreStrategic or Co-development PartnerOne of oldest medical training institutes in Europe. Hosts ESR12 on end-to-end test workflow development. Collaborates with MedAustron for beam access.
• Politecnico di MilanocoreStrategic or Co-development PartnerCartCas group develops technologies for high-precision radiation oncology. Hosts ESR5 on 4D MR Imaging and motion modelling. Strategic collaborations with CNAO.
• University of AmsterdamcoreStrategic or Co-development PartnerResearch-intensive university. Hosts ESR6 on optimizing Plan of the Day. Contributes operations research expertise for treatment optimization algorithms.
• University of Ljubljana (FMF)coreStrategic or Co-development PartnerLargest university in Slovenia and founding member of RAPTOR. Hosts ESR2 on automated segmentation and contour propagation. Medical Physics Research Program bridges clinical and research personnel.
• Massachusetts General Hospital (MGH)strategicStrategic or Co-development PartnerFounding member of RAPTOR consortium with University of Ljubljana and Cosylab. Hosts ESR6 secondments. Pioneering institution in proton therapy research.
• CNAO (Centro Nazionale di Adroterapia Oncologica)partnerStrategic or Co-development PartnerItalian National Center for Oncological Hadrontherapy. Hosts Online Adaptive PT Workshop events. Provides clinical environment for research activities.
• MedAustronpartnerStrategic or Co-development PartnerAustrian Proton- and Ion beam Center. Synchrotron facility used for phantom experiments by multiple consortium researchers. Collaborates with MedUniVienna.
• IBApartnerStrategic or Co-development PartnerWorldwide leader in proton therapy solutions. Developed knife-edge slit-camera prototype for prompt gamma imaging under EU project ENVISION. Partner for secondment activities.
• National Institutes for Quantum and Radiological Science and Technology (QST/NIRS)partnerStrategic or Co-development PartnerJapanese national institute. Hosts ESR15 secondments. International collaboration extending consortium reach to Asia-Pacific region.
• ESTROpartnerGTM or Marketing PartnerEuropean Society for Radiotherapy & Oncology. RAPTOR articles published in Young ESTRO Corner. Consortium presents at ESTRO conferences.
• EFOMPpartnerGTM or Marketing PartnerEuropean Federation of Organisations for Medical Physics. Endorses Advanced Medical Physics School organized by Italian Physics Society.
• VarianpartnerTechnology or IntegrationMedical technology company providing radiation therapy solutions. Listed as partner organization for potential technology integration.
• ProtonVDApartnerTechnology or IntegrationCompany developing range verification technologies. Hosts ESR15 secondments for proton radiography research.
• ElektapartnerTechnology or IntegrationMedical technology company. UMCG partnership for SMART clinic initiative and photon therapy research mentioned in postdoc position descriptions.
• ETH ZurichpartnerStrategic or Co-development PartnerSwiss Federal Institute of Technology. PSI PhD degrees awarded through ETH Zurich under supervision of Prof. Antony Lomax.
• KTH Royal Institute of TechnologypartnerStrategic or Co-development PartnerSwedish technical university. Hosts ESR11 secondments. Contributes to robust optimization research.
• KU LeuvenpartnerStrategic or Co-development PartnerBelgian university. Partner organization for consortium activities.
• INFNpartnerStrategic or Co-development PartnerItalian National Institute for Nuclear Physics. Partner organization for particle physics and therapy research.
• University of Turin (UNITO)partnerStrategic or Co-development PartnerItalian university. Dual-PhD arrangements for ESR8 (with Politecnico di Torino) mentioned.
• FHNW (Fachhochschule Nordwestschweiz)partnerStrategic or Co-development PartnerSwiss University of Applied Sciences. Partner organization for consortium activities.
• Grasshopper FilmsminorGTM or Marketing PartnerMedia production partner for dissemination videos and visual content creation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Elekta: Radiation therapy and radiosurgery incumbent with Unity MR-Linac and broader oncology software portfolio. RAPTOR partner via UMCG SMART clinic collaboration; competes in adaptive radiation therapy space.
• Hitachi (Proton Therapy Business): Major Japanese conglomerate operating proton therapy systems globally and conducting extensive adaptive particle therapy research. Comparable as a large incumbent advancing OAPT from a hardware-led perspective.
• Varian Medical Systems (Siemens Healthineers): Broad radiation oncology incumbent with Ethos adaptive radiotherapy platform and Hyperion arc therapy. RAPTOR partner organization; competes with consortium's adaptive workflow research via commercial adaptive photon therapy.

Direct peers

• Cosylab: Ljubljana-based control system integrator for particle therapy, founding member of RAPTOR. Hosts ESR9 on automated log-file QA; directly comparable as a vendor of particle therapy control systems and consortium commercialization partner.
• Mevion Medical Systems: US-based compact proton therapy system developer (MEVION S250i with HYPERSCAN pencil beam scanning). Comparable as a vendor making proton therapy more compact and economically viable — directly addressing RAPTOR's cost-reduction theme.
• IBA (Ion Beam Applications): World leader in proton therapy equipment and solutions, including the ProteusONE and ProteusPLUS systems. RAPTOR partner (ENVISION project, secondments); directly comparable as the incumbent proton therapy hardware vendor affected by consortium's adaptive workflow research.
• RaySearch Laboratories: Stockholm-based medical technology company developing treatment planning software for radiation therapy including adaptive proton therapy. RAPTOR partner and hosts ESR11 on robust optimization; directly comparable as the leading commercial OAPT treatment planning vendor.
• MedPhoton: Salzburg-based company developing robotic CBCT imaging systems (ImagingRing) for image-guided particle therapy. RAPTOR partner hosting ESR3 on CBCT enhancement; directly comparable as a developer of OAPT-enabling imaging hardware.

Emerging players

• Leo Cancer Care: UK/Irish company developing upright particle therapy systems (sitting/standing patient positioning). Comparable to RAPTORplus's research on upright patient positioning for compact beamline designs as a cost-reduction strategy.
• ViewRay: Developer of MRIdian MR-guided radiation therapy system combining real-time MRI with adaptive radiotherapy. Comparable as a commercial player advancing daily online adaptive radiotherapy — competing modality to RAPTOR's OAPT approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/raptor-consortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RAPTOR Consortium